Purpose The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH. Methods A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients).
Introduction
Aseptic non-traumatic osteonecrosis of the femoral head (ONFH) is a painful disorder which leads in 80% of cases to a total hip replacement (THR) [1] . Glucocorticoids and alcohol abuse are the most frequent risk factors for ONFH in Caucasians [2] .
The treatment of ONFH, particularly in fracture stages, remains challenging. Two specific features of ONFH emphasize the importance of developing a conservative surgical therapeutic approach since prosthetic replacements rarely last for their lifetime and could be required for more than one joint. Firstly, patients suffering from ONFH are young. In a recent ONFH cohort study the mean age was 48.4 years with the youngest being 19 years old [3] . Secondly, patients suffering from ONFH have a high risk of multiple surgical procedures. Indeed, multiple ON lesions are frequent: bilateral lesions were found in 63% of the patients and 11% had multifocal ON (more than 2 ON sites) [3] . Core decompression of the femoral head is the most widespread conservative surgical procedure proposed to treat ONFH. Although this procedure has already been employed for more than five decades [4] , its efficacy remains controversial [5, 6] . The success rate for core decompression is even worse when a subchondral fracture (47% in ARCO stage 3) is present compared to the precollapse stages (85% in ARCO stage 1 and 65% in ARCO stage 2) [1, 7] .
Recent publications suggested that ON might be a disease of bone cells and mesenchymal stem cells (MSC) [8, 9] . The activity levels together with the number of MSC in the bone marrow is depressed in patients with ONFH [8] . The replication capacity of osteoblastic cells is decreased in the proximal femur of patients with ONFH [9] . The apoptosis of osteoblasts and osteocytes is increased especially in the so-called creeping substitution surrounding the necrotic region [10] . These findings raised the possibility that bone marrow containing MSC implanted into the necrotic lesion of the femoral head could be useful. A two year prospective controlled study showed that, in unfractured ONFH cases, the implantation of autologous bone marrow aspirate concentrate (BMAC) into the necrotic lesion through a core decompression procedure was more effective than core decompression alone in improving pain and hip function and reducing the number of hips that progressed to subchondral fracture [11] . The course of the disease over 24 months was deemed satisfactory in 90% of the hips in the BMAC group compared to 37.5% in the control group. This positive effect was confirmed in a five year follow-up study [12] .
The natural evolution of ON stage 3 seems poor, with 87% of cases requiring THR, which may be reduced to 53% after core decompression [1] . A beneficial effect -reduction of both functional evolution and need for THR -has also been reported in fracture ONFH [13] . The purpose of the present study was, therefore, to evaluate the effect of the addition of BMAC implanted in the necrotic lesion in comparisonn with a core decompression alone in ARCO stage 3 ONFH. We initiated a randomized controlled trial (RCT) on the effect of BMAC implantation into the necrotic lesion of fracture stages ONFH using the same technique as previously described [14] .
Patients and methods
The study was conducted in two university centers: Hôpital Erasme, Université de Bruxelles and CHU de Liège, University of Liège. Osteonecrosis was diagnosed by X-rays and MRI for each case [15] . The ON staging used was the ARCO classification system using X-rays and MRI [16, 21] .
The primary objective was to confirm, in ARCO stage 3 ONFH, the BMAC injection's effect on the need for a THR.
The secondary objectives were to evaluate the advantage produced by BMAC concerning pain, functional ability, progression of ON lesions in terms of location, extension, surface collapse, dome depression evolution, and appearance of osteoarthritis features (evolution to ARCO stage 4).
The inclusion criteria were patients aged 18 years or older suffering from ARCO stage 3 non-traumatic ONFH with a surface collapse lower than 30% of the entire articular surface together with a dome depression of no more than 4 mm, and who had signed the written consent form. The exclusion criteria were evidence of malignant disorder in the past five years, contraindication to undergo an MRI, or a positive serological test for HIV, hepatitis B or hepatitis C.
Randomization
A centralized assignment to treatment groups was performed for the two centres. The subject under investigation was patient's hip. We therefore randomly allocated hips to a core decompression procedure associated with BMAC implantation (BMAC group) or saline implantation (control group). In case of eligibility, hips were allocated through a randomization process to one of the two study arms, with a ratio 1:1. A randomization list was generated, using random permuted blocks of two letters. Randomization was adapted for bilateral lesions because the bone marrow aspiration volume had to be limited for ethical reasons and MSC numbers decrease in larger bone marrow collection volumes [17] When the two hips (of the same patient) affected with ONFH were enrolled in the study, the right hip was assigned to the treatment arm from the first available envelop. The other hip was then assigned to the other treatment arm, using the next available envelop with said assignment, in order to ensure exactly equal treatment numbers as specified in the randomization code.
As proof-of-concept study, an optimal sample size was impossible to calculate. No formal sample size calculation was performed. Sixty subjects (hips) were planned to be enrolled. This number was considered sufficient to document the efficacy and safety.
This study was a double-bind study: participants and outcome assessor (clinicians and radiologists) were unaware of which treatment assignment was which. Treating clinicians were not masked to treatment assignment.
Core decompression and BMAC procedures
The procedures were previously published [14, 18] . Under general anaesthesia, a volume of 400 mL of bone marrow was harvested from the posterior iliac crests and was sorted on a Spectra cell separator (777,006,300; Cobe, Lakewood, Colorado) and concentrated to a final volume of 50 ml. During the same general anaesthesia, a special 4 mm trephine was inserted under control of a fluoroscopic view through the great trochanter, the neck, and the femoral head in the necrotic lesion. Then the BMAC (BMAC group) or saline 50 ml (control group) was injected into the necrotic region. To avoid any leakage, a Gelfoam® absorbable gelatin sponge (Pharmacia & Upjohn Company, Kalamazoo, MI 49001, USA) was pushed through the trephine to close the hole. In the control group, a sham skin incision was done at the site of bone marrow harvesting. So, the patients were unaware of the treatment received.
Clinical evaluation
Two investigators, unaware of the treatment group assignments, performed all the post-operative outcome assessments. Patients were assessed at baseline, three, six, 12, and 24 months. Patients' assessments of pain included a visual analogue scale (VAS) from 0 mm (no pain) to 100 mm (severe pain) [19] . Symptoms were also assessed by the subscales A and B (both dedicated to the hip status) of the WOMAC score [20] . In the case of hip bilateral involvement, patients were asked to complete a separate questionnaire for each hip. During each visit, safety was assessed by recording adverse events and serious adverse events. The decision to possibly turn to THR when the treatment had been insufficient in controlling pain and/or disability, was discussed with the patient at the end of each assessment session. The final decision was taken according to the patient's own wishes.
Radiological evaluation
Anteroposterior and frog leg view weight-bearing radiographs and an MRI study were taken at baseline, three, six, 12, 18, and 24 months. Radiological progression of ONFH was measured by reference to the ARCO staging [16, 21] For location and quantification of ON lesion, the ARCO subclassifications were used [16, 21] . The location of the ON lesion under a weight-bearing dome of the acetabulum was A = medial, B = central, C = lateral; the extension of the lesion (a calculation of the area of femoral head involvement) was: A = < 15%, B = 15-30%, C = > 30%. The surface collapse extension was, after selection of the most prominent view, expressed as a percentage of the entire articular surface: A = < 15% involvement, B = 15-30% involvement, C = > 30% involvement. The dome depression was expressed as A = a depression of less than 2 mm, B = 2-4 mm, and C = more than 4 mm. A single reader, unaware of the treatment assignments, analyzed all radiographs and MRI.
Statistical methods
Continuous variables were given by their mean ± SEM; their means were compared between two independent groups with Student t-tests, or with Welch tests in the case of variance heterogeneity. Qualitative variables were given by their proportions and were compared between independent groups with Fisher's exact chi-square tests.
All statistical analyses were performed using the statistical software IBM-SPSS-V22.0. A statistically significant effect was considered as soon as the p-value was lower than 0.05.
Results
The cohort formation is summarized in the CONSORT flow diagram (Fig. 1) . We screened 60 hips from 46 patients (14 patients with bilateral stage 3 ON). We could randomize 52 hips/42 patients (ten with bilateral stage 3 ON) in the two groups. Finally, we were able to evaluate 23 hips from 19 patients (eight with bilateral stage 3 ON) in the BMAC group and 23 hips from 19 patients (eight with bilateral stage 3 ON) in the control group.
The baseline demographic characteristics are presented in Table 1 . No statistical differences between both groups were found in terms of gender, age, BMI, side of unilateral ON, duration of symptoms, bilateral and multifocal ON presentations, risk factors, pain, and WOMAC scoring. The hips displayed similar fracture ARCO stage 3 ONFH in terms of location and extension of ON lesions, surface collapse, and dome depression.
The BMAC had a final volume of 48.33 ± 1.16 ml. The mean number of nucleated cells injected was 3.46 ± 0.36 × 10 9 including 1.5 ± 0.28% CD34 + . The mean number of Fibroblast colony forming units (CFU-F) was 19.45 ± 3.51 × 10 6 nucleated cells. At the 24-month follow-up, no difference was found between groups of either the primary or secondary endpoints ( Table 2) .
The primary objective was to confirm the effect of BMAC on the need for a THR. In the BMAC group 15 hips and in the control group 23 hips needed a THR (p = 1.000). The time to The secondary objectives were to evaluate the advantage produced by BMAC concerning pain, functional ability, progression of ON lesions in terms of location, extension, surface collapse, dome depression evolution, and appearance of osteoarthritis features (evolution to ARCO stage 4). No significant improvement of pain (VAS) or functional ability (WOMAC subscales A and B) was found in the BMAC group. An evolution to stage 4 was noted in ten hips (43%) in the BMAC group after 9.9 ± 2.6 months and nine hips (43%) in the control group after 9.3 ± 2.2 months (p = 0.871). The ON lesions were only increased in a few hips (Table 2) . Concerning the quantification of the ON lesions in the BMAC group versus control group, ON location was worsened in two hips (9%) versus one (5%), extension in one hip (5%) versus one hip (5%), surface collapse in ten hips (43%) versus eight hips (38%), and dome depression in seven hips (30%) versus six hips (29%). These ON lesion evolutions showed no statistical difference between the two groups (p-values between 0.637 and 1.000) and were not related to the need of THR (p = 1.000).
The survey of potential side effects did not reveal any serious adverse event. Few adverse events were reported: pain at the great trochanter in four cases (one in the BMAC group) and at the iliac crest in two (two in the BMAC group), fever for less than 24 hours with negative bacteriological investigations in two cases in the BMAC group and nausea in two cases (one in the BMAC group).
Discussion
Our RCT has not confirmed the advantage of BMAC implantation in comparison with core decompression alone in ON stage 3. No statistically significant difference has been observed between the core decompression plus saline injection (control group) and the core decompression plus BMAC (implantation group) concerning the need for a THR, the evolution of pain and functional ability, the evolution of the necrotic lesion, and the appearance of osteoarthritis.
A review of the available literature revealed that no other RCT evaluating the effect of BMAC implantation or other cell-based treatments in stage 3 ONFH was published. We RCT = randomized controlled trial. THR = total hip replacement. Mini core = core with 3.5 to 5 mm outer diameter trephine only found publications where fractured ONFH were only a part of the studied cases (Table 3) . Hernigou et al. reported a cohort study of ONFH treated with the same protocol as the one we used: mini core decompression and BMAC implantation in the necrotic area [13] . In this study, ON Steinberg stages 3 (no flattening of more than 1 mm) and 4 (flattening of more than 1 mm without joint narrowing) were similar to our ON population although the definition of the staging was slightly different because we used the ARCO reference (no flattening more than 4 mm). A second difference was the follow-up duration: more than five years in the Hernigou study versus two years in our study. Arthroplasty was needed in 5/12 ON stage 3 (42%), and, in our study, in 15/23 hips (65%). Some differences were found concerning the aetiological factors: more cases having alcohol abuse and sickle cell disease were present than in our study in which more patients had received corticosteroids. However, sickle cell disease seems to confer a worse ON prognosis [22] . So, the differences remained inexplicable. In another publication, a cohort study of BMAC treatment in ON included nine ARCO stage 3A ONFH with a follow-up of 27, six months [23] . The radiological progression occurred in 33, 3% and only 1/9 required a THR. Finally, a retrospective study reporting nine hips in six SLE patients treated with corticoids included three Japanese orthopaedic stage 3 ONFH [24] . After a minimum follow-up of three years, 1/3 hips had a radiological worsening and a THR requirement. These results are better than those of our study, but they are vitiated by some weaknesses: no control group and retrospective case reports. Some limitations also exist in our study: many drop out reducing the studied cohort, the lack of sample size calculation, and the inclusion of bilateral ONFH. Absence of statistical effect does not however mean no effect as this could be attributed to too small sample sizes, but nevertheless no trend toward any difference was detected. So the rationale for further increasing the sample sizes has not been estimated relevant notably taking into account the difficulty of gathering the required patient's data.
Further regenerative therapy programs, using the RCT methodology, should further assess the therapeutic values of such programs including cell implantation, growth factors, and scaffolds.
In our study, the evolution of the ON lesions (extension, worsening of the subchondral bone collapse, evolution to osteoarthritis) was not correlated to the need of THR. In both groups the worsening of ON was very limited (Table 3 ). In ONFH, the need for THR could be related not only to a worsening of the collapse but also to other factors such as synovitis, cartilage lesions, or periarticular disturbances. Interestingly, a therapeutic approach of ONFH dedicated to mechanical stabilization of the collapse by cementation was ineffective [25] . A more precise analysis of lesion size based on the MRIs would confirm this lack of relationship between clinical failure and worsening of the bone collapse.
In conclusion, our study did not find any significant improvement of ON evolution in stage 3 ONFH when BMAC implantation in the necrosis is added to core decompression.
